Valneva said on May 4 the French drugmaker will conduct a trial about the use of the company’s COVID-19 vaccine candidate VLA2001 as a booster jab following a mRNA vaccination or natural infection.
Moderna Inc. on May 4 forecast higher vaccine sales for the second half of 2022 than in the first six months of the year, as the company expects the virus that causes COVID-19 to follow a more seasonal pattern requiring booster shots in the fall.
Asthma in children may worsen after an infection with the coronavirus, doctors warn. Additionally, among people who were previously infected with the coronavirus, a third dose of an mRNA vaccine from Pfizer/BioNTech or Moderna may not boost their protection against the Omicron variant of the virus, according to new data.
Moderna Inc.’s chief medical officer said on Sunday the company’s vaccine for children under 6 years old will be ready for review by a Food and Drug Administration panel when it meets in June.
AstraZeneca’s Phase III Provent trial results showed a statistically significant 77 percent decrease in a patient’s likelihood of developing symptomatic COVID-19 when proactively treated with Evusheld. Additionally, results were announced by Clover Biopharmaceuticals for the Phase II/III Spectra global study investigating the efficacy of the SCB-2019 (CpG 1018/Alum) vaccine booster in patients that have previously developed a COVID-19 infection.
Arcturus Therapeutics announced positive Phase III trial results for the company’s mRNA vaccine candidate ARCT-154, which is intended to prevent COVID-19 caused by the SARS-CoV-2 virus.
ReutersModerna Inc. on April 19 said a COVID-19 booster designed to target the Beta variant as well as the original coronavirus generated a better immune response against a number of virus variants including Omicron.
A fourth dose of the COVID-19 vaccine from Pfizer and BioNTech provided significant added protection against severe disease, hospitalization and death for at least a month in older individuals, according to a study from Israel conducted when the Omicron variant was dominant. Additionally, new findings suggest patients with COVID-19 may have an increased risk of rare vision-threatening blood clots in the eye for months afterward.
A third dose of the COVID-19 vaccine from Pfizer (PFE.N) and BioNTech (22UAy.DE) produced significant protection against the Omicron variant of the coronavirus in healthy children ages 5 to 11, the companies said on April 14.
ReutersTop U.S. Food and Drug Administration officials on April 6 said the agency is aiming to decide by June whether to change the design of COVID-19 vaccines in order to combat future variants, even if it does not have all the necessary information to measure their effectiveness.
